Create various new sections of KRS Chapter 367 to define terms; to prohibit manufacturers and wholesalers of off-patent or generic prescription drugs from engaging in unrestricted price increases; to require the secretary of the Cabinet for Health and Family Services to report certain price increases to the Attorney General; to establish that certain price increases for off-patent or generic drugs constitute a violation of KRS 367.170; establish penalties.